Skip to main content
OpenTrials
Completed

NCT Number: NCT04493021

Evaluation of the Dermal Cooling System for the Enhanced Treatment of Benign Pigmented Lesions and Common Skin Conditions

The purpose of this study is to evaluate the Dermal Cooling System for lightening of benign pigmented lesions and to assess additional cosmetic benefits.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sculptology

Pleasanton, California, 94566, United States

About this study

This is a prospective, non-randomized, open-label study to evaluate the effectiveness of the Dermal Cooling system to reduce pigmentation in benign pigmented lesions and to determine if additional cosmetic benefits are achieved.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects > 18 years of age.
  • Subject has one or more benign pigmented lesions (e.g., solar lentigines, freckles, seborrheic keratosis), in an area suitable for treatment.
  • Subject is willing to have up to 40 treatment sites treated per treatment session depending on the size and nature of the lesions identified.
  • Subject is willing to have digital photographs taken of the treatment area and agrees to use of photographs for presentation, educational, or marketing purposes.
  • Subject is willing to cover treated area or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated area for the duration of the study, including the follow-up period, if requested.
  • Subject has read and signed a written informed consent form.
  • Subject is willing to comply with adjuvant topical regimen, as applicable. -

Exclusion criteria

  • Physician prescribed medical or surgical treatment, or use of over-the-counter products to alter skin color, in the area of intended treatment in the previous 6 months (e.g., hydroquinone, corticosteroids, laser surgery)
  • Use of products containing glycolic acids, retinol, salicylic acid within the previous 2 weeks
  • Use of Accutane within the previous 6 months
  • Artificial tanning in the area of intended treatment within 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period
  • Scars or tattoos in the location of the treatment sites
  • History of melasma, vitiligo, eczema, or psoriasis in the area of treatment
  • History of melanoma
  • Subject is pregnant or intending to become pregnant during the study period
  • Subject is lactating or has been lactating in the past 6 months
  • Known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia, cold urticaria, paroxysmal cold hemoglobinuria, Reynaud's disease.
  • History of abnormal wound healing or abnormal scarring
  • Inability or unwillingness to comply with the study requirements.
  • Current enrollment in a clinical study of any other unapproved investigational drug or device.
  • Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.

-

Treatment and study plan

Dermal Cooling System

Device

Controlled localized cooling will be applied to benign pigmented lesions using the Dermal Cooling System

Primary outcomes

  1. Improvement in the appearance of the treated areas as assessed by Investigator assessment.

    Time frame: 2-Month Follow-up visit

    Investigator assessment using Global Aesthetic Improvement Scale (GAIS); graded from "4" (very much improved") to "0" (worse).

  2. Safety of the treatment

    Time frame: Up to 12 months

    Determined by incidence of device-or procedure-related adverse events

Sponsors and collaborators

Lead sponsor

R2 Dermatology

Industry

Registry information

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Jul 30, 2020
Registry last updated
Aug 30, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.